LENZ Therapeutics, Inc.
LENZ Therapeutics, Inc. (LENZ) Stock News
The latest LENZ headlines and market coverage — 2 recent stories, updated throughout the day.
- GlobeNewswire Inc.·
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ
Pomerantz LLP is investigating potential securities fraud claims against LENZ Therapeutics following disappointing Q2 2026 earnings. The company reported flat organic product sales of $1.73 million for its primary eye drop VIZZ, with most revenue ($3.8M of $5.5M total) coming from one-time licensing milestones. Bank of America subsequently downgraded the stock from 'Buy' to 'Neutral' and slashed its price target from $31 to $7, citing slower-than-expected commercial launch performance.
- GlobeNewswire Inc.·
LENZ Therapeutics Announces Everest Medicines Acquired Rights to Develop and Commercialize VIZZ® (LNZ100) in Greater China
LENZ Therapeutics announced that Everest Medicines has acquired rights to develop and commercialize VIZZ (LNZ100) in Greater China through an Asset Purchase Agreement with Corxel Pharmaceuticals. The New Drug Application for LNZ100 was submitted to China's NMPA in September 2025 with approval anticipated in Q1 2027. LENZ is eligible to receive up to $85 million in regulatory and sales milestones plus tiered royalties on net sales.